1. Clinical experience with Cerebrolysin.
- Author
-
Molloy DW and Standish TI
- Subjects
- Alzheimer Disease diagnostic imaging, Alzheimer Disease psychology, Amino Acids administration & dosage, Amino Acids adverse effects, Brain metabolism, Cognition drug effects, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Neuropsychological Tests, Nootropic Agents administration & dosage, Nootropic Agents adverse effects, Randomized Controlled Trials as Topic, Reference Values, Tomography, Emission-Computed, Alzheimer Disease drug therapy, Amino Acids therapeutic use, Nootropic Agents therapeutic use
- Abstract
Cerebrolysin is a peptidergic drug which displays neurotrophic action in various animal models. It is used for the treatment of dementia and in this report we provide evidence for the long-term clinical efficacy of Cerebrolysin in Alzheimer's disease. This evidence is based on our clinical experience with Cerebrolysin, stemming from our participation in a double-blind, placebo-controlled clinical trial, a compassionate use programme initiated thereafter, and a PET study. Our data suggests, that Cerebrolysin is a safe and effective treatment for Alzheimer's disease and that repeat treatments may maintain function in patients over the long-term.
- Published
- 2000